PACIFIC KNOWLEDGE SYSTEMS WINS MAJOR TENDER IN WESTERN AUSTRALIA

February 8, 2005: The Board of BioTech Capital Ltd (ASX:BTC) is pleased to announce that investee company, Pacific Knowledge Systems Pty Ltd (PKS), has been successful in winning a tender to provide PathCentre, the Western Australian Centre for Pathology and Medical Research, with a range of human clinical pathology IT support services utilising its proprietary decision support software. The precise terms of the contract are confidential.

The laboratory software developed by Pacific Knowledge Systems – known as LabWizard™ - assists in the interpretation and reporting of pathology results and is considered the most advanced pathology tool on the market. LabWizard™ provides tailored patient-specific reports putting the laboratory's expertise in the clinician's hands and improving the quality of information and care patients receive.

The CEO of Pacific Knowledge Systems, Mr Bruce McConochie, explained that "Today's clinicians are faced with the many challenges of patient consultation, processing and recalling large amounts of information, and making informed decisions on the patient's behalf, all within a restricted time period. The LabWizard™ product helps clinicians because it systematically harnesses the combined knowledge, experience and judgment of the organisation's expert pathologists to make recommendations about the appropriate course of action to take in regards to a specific patient. The result is pathologists provide timelier, higher quality patient specific reports to doctors."

The Director of Operations at PathCentre, Mr David Taylor, said using "Pacific Knowledge Systems software solution will assist PathCentre maintain its world best standards in West Australian pathology."

PKS has built a base of customers in the domestic Australian pathology market and the number of interpretations being provided by LabWizard™ has increased exponentially over the past two years. Currently LabWizard™ is generating over 500,000 patient reports each month across a number of teaching hospitals and for-profit labs.

The award of the PathCentre contract follows the signing of a pilot agreement in late 2004 with STAR Laboratories of the Netherlands to pilot the LabWizard™ System. STAR Laboratories is the leading pathology laboratory in The Netherlands.

The collaboration with STAR Laboratories is a unique opportunity offering PKS a prestigious international reference site that is intended to serve as a beachhead into the broader European market. Given the large number of patients that STAR Laboratories handles on a daily basis it provides the company with an opportunity to rapidly generate data and demonstrate its value to other prospective customers in the European market.

The company is currently in negotiations with several other laboratories at other locations in Europe and North America to expand its presence in these key offshore markets.

Pacific Knowledge Systems is also expanding its product suite, with new applications for existing clients within pathology industry and new clients in new industries. These products are in use, being piloted or committed to pilot at a number of sites including ACT Pathology, IMVS Adelaide, Gribbles Laboratories, Westmead Hospital (ICPMR), Mater Brisbane and Prince of Wales Hospital (SEALS).

Currently under development is a new product which gives the user the ability to easily access and filter data for research purposes. This development is currently being sponsored by one of the world's largest pharmaceutical companies. If early success can be translated into a sustained market opportunity this provides the company with the potential to significantly expand it's revenue base.

About BioTech Capital Ltd (www.biotechcapital.com.au)
BioTech Capital Ltd ("BTC") is one of Australia's largest life-science focused private equity funds. With approximately $10 million in investment funds still available, the company is well placed to continue to develop a diversified portfolio of high quality Australian life-science investments.

BTC currently has investments in a diverse group of Australian life-science companies including Alchemia, Biocomm, Clinical Cell Culture, Continence Control Systems, Pacific Knowledge Systems, Phylogica, Prima Biomed, Proteome Systems, Starpharma, Stem Cell Sciences and XRT.

As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income.

BTC is listed on the Australian Stock Exchange (Code: BTC, BTCOA) and is managed externally by Titan BioVentures Management (www.titanbioventures.com).

Contact Information

PR and IR	BioTech Capital Ltd	Pacific Knowledge Systems
Rebecca Christie Buchan Consulting (02) 9237 2800 0417 382 391 rchristie@bcg.com.au	Harry Karelis Managing Director 0413 056 328 hkarelis@titanbioventures.com	Bruce McConochie Chief Executive Officer 0439 474 129